Collegium Pharmaceutical Inc - Company Profile
Powered by 
All the sales intelligence you need on Collegium Pharmaceutical Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Collegium Pharmaceutical Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Collegium Pharmaceutical Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Collegium Pharmaceutical Inc (Collegium) is a specialty pharmaceutical company that focuses on the development and commercialization of innovative drugs for treating patients suffering from pain. It develops products based on its DETERx platform technology. DETERx offers extended-release drug delivery, while protecting against common methods of abuse and tampering. The company's lead product, Xtampza ER is designed to provide adequate pain control. Its other products include Nucynta ER for the treatment of chronic pain and neuropathic pain associated with diabetic peripheral neuropathy, and Nucynta IR for the management of acute pain severe enough to require an opioid analgesic. The company distributes its products through wholesalers to retail outlets, managed healthcare organizations, and government agencies. Collegium is headquartered in Stoughton, Massachusetts, the US.
Headquarters
United States of America
Address
100 Technology Center Dr, Stoughton, Massachusetts, 02072-4710
Website
www.collegiumpharma.com
Telephone
1 781 7133699
No of Employees
423
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
COLL (NASD)
Revenue (2024)
$780.6M
23.6%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-9.1%
(2024 vs 2023)
Market Cap*
$1.2B
Net Profit Margin (2024)
XYZ
-26.6%
(2024 vs 2023)
* As of and is in US$
Collegium Pharmaceutical Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Xtampza ER | Xtampza |
| Belbuca | Nucynta |
| Symproic | Belbuca |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In May, the company entered into an Accelerated Share Repurchase ("ASR") agreement with Jefferies LLC to repurchase US$25 million of the company’s common stock. |
| 2024 | Acquisitions/Mergers/Takeovers | In September, the company acquired Ironshore Therapeutics, a pharmaceutical company, for US$525 million. |
| 2022 | Acquisitions/Mergers/Takeovers | In March, the company acquired BioDelivery Sciences International, a commercial-stage specialty pharmaceutical company. |
Competitor Comparison
| Key Parameters | Collegium Pharmaceutical Inc | Supernus Pharmaceuticals Inc | Shionogi Inc | Acura Pharmaceuticals Inc | Filana Therapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Stoughton | Rockville | Florham Park | Palatine | Austin |
| State/Province | Massachusetts | Maryland | New Jersey | Illinois | Texas |
| No. of Employees | 423 | 778 | - | - | 17 |
| Entity Type | Public | Public | Private | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Gino Santini | Chairman | Executive Board | 2025 | 69 |
| Vikram Karnani | Director; Chief Executive Officer; President | Executive Board | 2024 | 51 |
| Colleen Tupper | Chief Financial Officer; Executive Vice President | Senior Management | 2021 | 50 |
| Dean J. Patras | Chief People Officer | Senior Management | 2025 | - |
| Thomas B. Smith | Chief Medical Officer; Executive Vice President | Senior Management | 2022 | 64 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer